Key result
Essential hypertension linked to ~5-point lower prevalence of HLA B15 versus healthy controls.
Case-Control (n=1,084)
Answers are grounded in this paper and cite their sources.
Human leucocyte AB antigens were determined by means of a lymphocyte toxicity test in 84 patients with essential hypertension and in 1000 blood donors. 2. The prevalence of HLA B8 was 16.4% in hypertensive patients and 8.9% in controls (P = 0.07). 3. The prevalence of HLA B12 was 34.5% in hypertensive patients and 26.9% in the control group (N.S.). In WHO stage III hypertension HLA B12 was found in six out of 10 patients. 4. The prevalence of HLA B15 was 1.2% in hypertensive patients and 6.4% in controls (P less than 0.05). 5. In view of a previous report of HLA antigens in Spanish diabetic population, this study does not support the suggestion of a genetic and possibly HLA-linked connection between essential hypertension and diabetes mellitus among the Spanish population. 6. A positive family history of hypertension tended to be more common in those patients with essential hypertension associated with HLA B8.
No takes yet. Share an insight, caveat, or question.
Fernández‐Cruz et al. (1981) conducted a case-control in Essential hypertension (n=1,084). Essential hypertension vs. Blood donors was evaluated on Prevalence of HLA B15 (p=<0.05). Essential hypertension in Spanish patients was associated with a lower prevalence of HLA B15 compared with blood donor controls.
Synapse has enriched 10 related papers. Consider them for comparative context: